SeaStar Medical Reports Third Quarter 2026 Financial Results - SEASTAR MEDICAL HOLDING CORP

Explicit Guidance:

• 2026 Full-Year Revenue: Management expects to exceed the $2 million guidance for QuellImmune revenue, driven by 247% YoY growth in Q3 ($630k) and cumulative nine-month revenue of $1.7 million. No specific updated number provided.
• 2027 Revenue Guidance: Explicit 2027 revenue guidance will be provided "earlier in 2027."
• Clinical Enrollment Completion: Anticipated completion of the neutralized AKI pivotal trial enrollment by mid-year 2027 (adjusted from prior expectations due to restrictive eligibility criteria).
• PMA Submission Timeline: Anticipates filing the final PMA module approximately nine months after completing trial enrollment (projected Q1 2028).
• FDA Approval Timeline: Anticipates FDA approval potentially in Q1 2029 or the first half of 2029, noting that regulatory review timelines are controlled by the FDA (standard 180-day window) but could be shortened via the modular PMA process.

Business-Segment Outlook:

• QuellImmune (Pediatric AKI): Expect "growing enthusiasm" and continued adoption in 2027; strategy focuses on the top 50 pediatric medical centers (20 current customers, +10 new in 2026) with plans to continue adding sites and increasing utilization at existing sites.
• Adult AKI Indication: The pivotal RCT is 75% enrolled (251/339 patients); enrollment completion targeted for mid-2027.
• Adult Sepsis Indication: Anticipates generating "significant data" on sepsis impact from the ongoing adult AKI trial's pre-specified analysis (expecting >70% of trial patients to have sepsis/Septic condition); plans to move "quickly" to submit data to the FDA for this indication if results are positive.
• Pipeline Expansion: SCD therapy has now received Breakthrough Device Designation for a 7th indication (Adult Sepsis); management highlights the "disease-agnostic potential" to address dysregulated inflammation across multiple serious conditions.
• Regulatory/Reimbursement: FDA confirmed compliance with the mandatory post-approval SAVE registry (previously a barrier); CMS has assigned ICD-10 PCS codes, enabling hospitals to bill for the therapy, which is expected to smooth customer adoption.

Market and Competitive Outlook:

• Demand Trends: Strong demand for QuellImmune in the ultra-rare pediatric AKI market; momentum is building in educating the critical care pediatric community regarding statistically significant higher survival rates (65% vs 47% historical cohort).
• Adoption Drivers: Removal of mandatory SAVE registry requirements and availability of billing codes are expected to reduce institutional friction and increase the attractiveness of QuellImmune for hospital systems.
• Target Market: Continued focus on a concentrated group of top 50 pediatric centers rather than broad market expansion, given the ultra-orphan nature of the condition.

Macro / Industry Outlook:

• Clinical Context: Management emphasizes the "urgent need" for better options in sepsis-associated AKI and multiple organ failure, citing high mortality rates (historically <50% survival in comparable cohorts).
• Regulatory Environment: FDA Breakthrough Device Designation is viewed as a positive signal for priority review and accelerated pathways for life-threatening conditions.

Strategic Initiatives:

• Clinical Trial Acceleration: Adding new clinical sites to accelerate enrollment; currently 4 sites added with more activation targeted by year-end.
• Modular PMA Strategy: Actively preparing and submitting PMA modules in advance of final clinical results to potentially parallelize review and approval processes.
• Data Generation: Executing pre-specified statistical analyses within the ongoing adult AKI trial to support both the primary AKI indication and the sepsis indication simultaneously.

Risks and Headwinds to Outlook:

• Enrollment Delays: Trial enrollment timeline extended due to strict inclusion/exclusion criteria designed to ensure a well-defined study population and rigorous evaluation of FCB potential benefit; management notes the timeline "could shorten" but prefers caution.
• Regulatory Uncertainty: Final PMA approval timelines are subject to FDA review speed (potentially the standard 180 days) and cannot be fully controlled by the company.
• Market Size Constraints: The ultra-rare nature of pediatric AKI limits the total addressable patient volume and requires a focused, resource-intensive sales strategy.

Management Tone on the Future:

• Confidence Level: High confidence in the clinical data ("statistically significant higher survival") and the strategic value of the Breakthrough Designation.
• Sentiment: Disappointed by the enrollment timeline extension but prioritizes "optimized outcome" and patient safety over speed.
• Hedges: Uses cautious language regarding the mid-2027 enrollment completion ("we would like to be cautious in our prediction") and avoids specific revenue numbers for 2027 pending early next year.

Miscellaneous:

• Financial Context: Q3 2026 net loss was $4.5M; Q3 2027 net cash balance was $4M (excluding $3.3M warrant exercises in October); R&D expenses increased due to clinical trial costs.
• Personnel: Dr. David Chung received the Combat Nephrology Award for contributions to renal support in high-acuity environments.